{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:25Z","timestamp":1792112245081,"version":"4.4.0"},"reference-count":37,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the pathophysiology is still poorly understood. The importance of this case report is to highlight the lack of robust evidence-based treatment for this emergency. We submit an approach to the pharmacotherapy of neuroleptic malignant syndrome based on the available evidence.<\/jats:p>","DOI":"10.64719\/pb.4581","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"84-91","source":"Crossref","is-referenced-by-count":4,"title":["An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome"],"prefix":"10.64719","volume":"49","author":[{"given":"Roland van","family":"Rensburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Decloedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870\u2013876.","DOI":"10.1176\/ajp.2007.164.6.870"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Wu YF, Kan YS, Yang CH. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson\u2019s disease \u2013 a case report. Gen Hosp Psychiatry. 2011;33(3):301.e7\u2013301.e8. doi: 10.1016\/j.genhosppsych.2010.11.013.","DOI":"10.1016\/j.genhosppsych.2010.11.013"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185.","DOI":"10.1016\/S0025-7125(16)30278-4"},{"key":"ref4","unstructured":"Pope HG, Aizley HG, Keck PE, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry. 1991;52(5):208\u2013212. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1674508."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Velamoor VR. Neuroleptic malignant syndrome. Drug Saf. 1998;19(1):73\u201382. doi: 10.2165\/00002018-199819010-00006.","DOI":"10.2165\/00002018-199819010-00006"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Sheehan R, Horsfall L, Strydom A, Osborn D, Walters K, Hassiotis A. Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open. 2017;7(8):e017406.","DOI":"10.1136\/bmjopen-2017-017406"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Henderson VW, Wooten GF. Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology. 1981;31(2):132. doi: 10.1212\/wnl.31.2.132.","DOI":"10.1212\/wnl.31.2.132"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry. 1991;158(6):850\u2013853.","DOI":"10.1192\/bjp.158.6.850"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mihara K, Kondo T, Suzuki A et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet. 2003;117B(1):57\u201360. http:\/\/doi.wiley.com\/10.1002\/ajmg.b.10025.","DOI":"10.1002\/ajmg.b.10025"},{"key":"ref10","unstructured":"Lew T, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry. 1983;18(12):1441\u20131446."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ebadi M, Pfeiffer R, Murrin L. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol. 1990;21(4):367\u2013386.","DOI":"10.1016\/0306-3623(90)90685-F"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Spivak B, Maline DI, Vered Y et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2000;102(3):226\u2013230.","DOI":"10.1034\/j.1600-0447.2000.102003226.x"},{"key":"ref13","unstructured":"Kato T, Yamawaki S. A pharmacological study of veratrine-induced hyperthermia in the rat: a model of neuroleptic malignant syndrome. Hiroshima J Med Sci. 1989;38(4):173\u2013181. http:\/\/europepmc.org\/abstract\/MED\/2637245."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Nemecek D, Rastogi-Cruz D, Csernansky JG. Atropinism may precipitate neuroleptic malignant syndrome during treatment with clozapine. Am J Psychiatry. 1993;150(10):1561.","DOI":"10.1176\/ajp.150.10.1561b"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Tanii H, Taniguchi N, Niigawa H et al. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. Brain Res. 1996;743(1\u20132):263\u2013270. doi: 10.1016\/S0006-8993(96)01059-1.","DOI":"10.1016\/S0006-8993(96)01059-1"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Velamoor VR, Norman RMG, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182(3):168\u2013173. doi: 10.1097\/00005053-199403000-00007.","DOI":"10.1097\/00005053-199403000-00007"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137\u20131145. doi: 10.1176\/ajp.142.10.1137.","DOI":"10.1176\/ajp.142.10.1137"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705\u2013713. doi: 10.1176\/ajp.148.6.705.","DOI":"10.1176\/ajp.148.6.705"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Medication-induced movement disorders and other adverse effects of medication. 5th. Washington, DC: American Psychiatric Publishing; 2013. pp. 709\u2013711. In: Diagnostic and Statistical Manual of Mental Disorders.","DOI":"10.1176\/appi.books.9780890425596.805970"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Gurrera RJ, Caroff SN, Cohen A et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222\u20131228.","DOI":"10.4088\/JCP.10m06438"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001;72(4):325\u2013336. doi: 10.1023\/a:1010389215197.","DOI":"10.1023\/a:1010389215197"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Reulbach U, D\u00fctsch C, Biermann T et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11(1):1\u20136.","DOI":"10.1186\/cc5148"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome: Focus on treatment and rechallenge. Ann Pharmacother. 2016;50(11):973\u2013981. doi: 10.1177\/1060028016657553.","DOI":"10.1177\/1060028016657553"},{"key":"ref24","unstructured":"Dantrolene. [Accessed 7 June 2018]; In: IBM Micromedex\u00ae DRUGDEX\u00ae (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http:\/\/www.micromedexsolutions.com\/"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982;56(4):254\u2013262. doi: 10.1097\/00000542-198204000-00005.","DOI":"10.1097\/00000542-198204000-00005"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Rosenberg MR, Green M. Neuroleptic malignant syndrome. Arch Intern Med. 1989;149(9):1927\u20131931. doi: 10.1001\/archinte.1989.00390090009002.","DOI":"10.1001\/archinte.1989.00390090009002"},{"key":"ref27","unstructured":"Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27(3):381\u2013384."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33(5):650\u2013659.","DOI":"10.1080\/j.1440-1614.1999.00630.x"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Wells AJ, Sommi RW, Crismon ML. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm. 1988;22(6):475\u2013480. doi: 10.1177\/106002808802200606.","DOI":"10.1177\/106002808802200606"},{"key":"ref30","unstructured":"Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989;50(8):295\u2013298. http:\/\/europepmc.org\/abstract\/MED\/2569457."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Woodbury MM, Woodbury MA. Case study: neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1161\u20131164. doi: 10.1097\/00004583-199211000-00028.","DOI":"10.1097\/00004583-199211000-00028"},{"key":"ref32","unstructured":"Lorazepam. [Accessed 7 June 2018]; In: IBM Micromedex\u00ae DRUGDEX\u00ae (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http:\/\/www.micromedexsolutions.com\/"},{"key":"ref33","unstructured":"Bromocriptine. [Accessed 7 June 2018]; In: IBM Micromedex\u00ae DRUGDEX\u00ae (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http:\/\/www.micromedexsolutions.com\/"},{"key":"ref34","unstructured":"Amantadine. [Accessed 19 June 2018]; In: IBM Micromedex\u00ae DRUGDEX\u00ae (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http:\/\/www.micromedexsolutions.com\/"},{"key":"ref35","unstructured":"Wijdicks EFM. Neuroleptic malignant syndrome. In: Aminoff MJ, editor. Waltham, MA: UpToDate; 2018. [Accessed 28 May 2018]. UpToDate. https:\/\/www.uptodate.com\/contents\/neuroleptic-malignant-syndrome."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22(2):389\u2013411.","DOI":"10.1016\/j.ncl.2003.12.006"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129\u2013135. doi: 10.1093\/bja\/85.1.129.","DOI":"10.1093\/bja\/85.1.129"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:34:45Z","timestamp":1791315285000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/an-approach-to-the-pharmacotherapy-of-neuroleptic-malignant-syndrome\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4581","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}